26.39
price up icon0.30%   0.08
pre-market  시장 영업 전:  26.30   -0.09   -0.34%
loading
전일 마감가:
$26.31
열려 있는:
$26.39
하루 거래량:
3.96M
Relative Volume:
2.56
시가총액:
$2.49B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.0788
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
-9.72%
1개월 성능:
-28.94%
6개월 성능:
-36.07%
1년 성능:
-37.98%
1일 변동 폭
Value
$25.81
$26.82
1주일 범위
Value
$25.81
$29.36
52주 변동 폭
Value
$25.81
$60.37

울트라제닉스 파마슈티컬 Stock (RARE) Company Profile

Name
명칭
Ultragenyx Pharmaceutical Inc
Name
전화
415-483-8800
Name
주소
60 LEVERONI COURT, NOVATO, CA
Name
직원
1,294
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
RARE's Discussions on Twitter

RARE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
26.39 2.76B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-28 개시 William Blair Outperform
2024-06-06 업그레이드 Goldman Neutral → Buy
2024-04-22 개시 RBC Capital Mkts Outperform
2023-12-08 개시 Wells Fargo Overweight
2023-06-14 재개 Credit Suisse Outperform
2023-06-06 업그레이드 Evercore ISI In-line → Outperform
2023-04-26 개시 Cantor Fitzgerald Overweight
2023-01-18 재개 Canaccord Genuity Buy
2022-12-30 재개 H.C. Wainwright Buy
2022-11-03 업그레이드 Robert W. Baird Neutral → Outperform
2022-10-13 업그레이드 Guggenheim Neutral → Buy
2022-08-01 다운그레이드 Evercore ISI Outperform → In-line
2022-03-16 업그레이드 Credit Suisse Neutral → Outperform
2022-02-11 업그레이드 JP Morgan Neutral → Overweight
2021-09-30 개시 H.C. Wainwright Buy
2021-08-19 개시 UBS Sell
2021-07-15 개시 Guggenheim Neutral
2021-06-29 업그레이드 BofA Securities Neutral → Buy
2021-06-04 재개 Robert W. Baird Neutral
2021-05-06 업그레이드 Citigroup Neutral → Buy
2021-05-06 업그레이드 Evercore ISI In-line → Outperform
2021-04-26 재개 Credit Suisse Neutral
2021-03-02 재개 Stifel Buy
2021-02-12 다운그레이드 JP Morgan Overweight → Neutral
2020-12-07 다운그레이드 Wedbush Outperform → Neutral
2020-11-24 재개 Evercore ISI In-line
2020-11-12 다운그레이드 BofA Securities Buy → Neutral
2019-08-02 재개 Wedbush Outperform
2019-03-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-02-22 재개 Raymond James Outperform
2019-01-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-11-08 업그레이드 Citigroup Sell → Neutral
2018-09-10 개시 Morgan Stanley Equal-Weight
2018-06-21 다운그레이드 Credit Suisse Outperform → Neutral
2018-05-11 업그레이드 Barclays Equal Weight → Overweight
2018-05-10 개시 Goldman Neutral
2018-04-18 업그레이드 SunTrust Hold → Buy
2018-03-22 재개 Piper Jaffray Overweight
2018-02-21 재확인 Stifel Buy
2018-01-22 업그레이드 Evercore ISI In-line → Outperform
2018-01-18 개시 Credit Suisse Outperform
2017-12-05 재확인 Barclays Equal Weight
2017-12-04 업그레이드 Jefferies Hold → Buy
2017-09-14 업그레이드 Wedbush Neutral → Outperform
모두보기

울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스

pulisher
06:39 AM

Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com

06:39 AM
pulisher
01:37 AM

What drives Ultragenyx Pharmaceutical Inc. stock priceFree Predictions - jammulinksnews.com

01:37 AM
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Ultragenyx Pharmaceutical Inc. stockExtraordinary market timing - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey

Jul 20, 2025
pulisher
Jul 20, 2025

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

Is Ultragenyx Pharmaceutical Inc. a good long term investmentTremendous return on equity - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 18, 2025

Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsPredictable High Return Trades - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey

Jul 17, 2025
pulisher
Jul 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyFree Exclusive Access to Stock Gurus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx Pharmaceutical Enters Oversold Territory (RARE) - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx Pharmaceutical (RARE): Balancing High-Stakes Catalysts with a Tightening Cash Runway - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx: The High Stakes Of Binary Events And A Short Cash Runway (RARE) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $55.00 by Analysts at Morgan Stanley - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Five things for pharma marketers to know: Tuesday, July 15, 2025 - Medical Marketing and Media

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx's Evkeeza Pediatric Approval Positions It as a Rare Disease Leader - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx’s MPSIIIA Gene Therapy UX111 Met With CRL - CGTLive®

Jul 14, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Ultragenyx Faces Delays After Setrusumab Misses Key Targets - Finimize

Jul 14, 2025
pulisher
Jul 14, 2025

FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst - Benzinga

Jul 14, 2025
pulisher
Jul 14, 2025

FDA rejects Ultragenyx gene therapy over manufacturing concerns - BioPharma Dive

Jul 14, 2025

울트라제닉스 파마슈티컬 (RARE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):